Theolytics, a biotech company aimed at producing curative cancer therapies, has named Carsten Reinhardt MD PhD as its new director, it was reported on Monday.
Dr Reinhardt is an oncology and biotech expert, with experience in translational development and early and late-stage clinical trial design, progressing multiple biological compounds from early preclinical development through first-in-man studies towards approvals in the US and Europe.
Dr Reinhardt is serving as the chief development officer and managing director of Immatics Biotechnologies GmbH. Prior to joining Immatics, he has served Micromet Inc as CMO and on the management board. He has also held the position of head of Clinical Development at Germany's Fresenius Biotech. He has also served at Hoffmann-La Roche.
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'